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ABSTRACT
The Ca2+-sensing protein calmodulin (CaM) inhibits cardiac ryanodine receptor (RyR2)-mediated Ca2+ 
release. CaM mutations associated with arrhythmias and sudden cardiac death have been shown to diminish 
CaM-dependent inhibition of RyR2, but the underlying mechanisms are not well understood. Nearly all 
arrhythmogenic CaM mutations identified are located in the C-domain of CaM and exert marked effects on 
Ca2+ binding to CaM and on the CaM C-domain interaction with the CaM-binding domain 2 (CaMBD2) in 
RyR2. Interestingly, the arrhythmogenic N-domain mutation CaM-N54I has little or no effect on Ca2+ binding 
to CaM or the CaM C-domain-RyR2 CaMBD2 interaction, unlike all CaM C-domain mutations. This suggests 
that CaM-N54I may diminish CaM-dependent RyR2 inhibition by affecting CaM N-domain interactions with 
RyR2 CaMBDs other than CaMBD2. To explore this possibility, we assessed the effects of deleting each of the 
four known CaMBDs in RyR2 (CaMBD1a, -1b, -2 or -3) on the CaM-dependent inhibition of RyR2-mediated 
Ca2+ release in HEK293 cells. We found that removing CaMBD1a, CaMBD1b, or CaMBD3 did not alter the 
effects of CaM-N54I or CaM-WT on RyR2 inhibition. On the other hand, deleting RyR2-CaMBD2 abolished 
the effects of both CaM-N54I and CaM-WT. Our results support that CaM-N54I causes aberrant RyR2 
regulation via an uncharacterised CaMBD or less likely CaMBD2, and that RyR2 CaMBD2 is required for the 
actions of both N- and C-domain CaM mutations. Moreover, our results show that CaMBD1a is central to 
RyR2 regulation, but CaMBD1a, CaMBD1b and CaMBD3 are not required for CaM-dependent inhibition of 
RyR2 in HEK293 cells.
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INTRODUCTION
The cardiac sarcoplasmic reticulum (SR) Ca2+ release channel (or ryanodine receptor type 2, RyR2) 
controls the intracellular release of Ca2+ stored in the SR in cardiomyocytes [1]. During cardiac excitation, a 
small influx of extracellular Ca2+ into the cytoplasm through voltage-gated Ca2+ channels (CaV1.2) activates 
RyR2 channels, embedded in the SR membrane, to release intracellularly stored Ca2+. This intracellular Ca2+ 
release increases the cytosolic free Ca2+ ([Ca2+]cyt) throughout the cardiomyocyte, and binding of Ca2+ to the 
myofilaments results in contraction. Ca2+ re-uptake to the SR and extrusion to the extracellular space then 
returns the cardiomyocyte to resting intracellular Ca2+ conditions [1,2]. Proper cardiac function requires 
intricate control of the Ca2+ release-uptake cycle, and therefore RyR2 activity is regulated by numerous 
proteins and signaling molecules, including the cytoplasmic Ca2+-sensing protein calmodulin (CaM) [1-5]. 
CaM has two Ca2+ binding domains (N- and C-domain) that each contains two Ca2+-binding EF-hand motifs, 
and CaM binds stoichiometrically to the homotetrameric RyR2 Ca2+ release channels (Figure 1).
CaM generally inhibits RyR2 Ca2+ release both at diastolic and systolic [Ca2+]cyt, and the tripartite 
interaction between the CaM C-domain, Ca2+ and the central CaM-binding domain (CaMBD2) in RyR2 is 
pivotal for CaM’s inhibition of RyR2 Ca2+ release, however both the N- and C-domain of CaM are required for 
adequate RyR2 regulation [1,4-14]. The two CaM domains have distinct affinities and kinetics for Ca2+ 
binding, and may therefore separately interact with different regions of RyR2 in a [Ca2+]cyt-dependent manner, 
but whether CaM’s inhibition of RyR2 involves more than one RyR2 region remains unclear [4-10,15,16]. 
Recent studies have coalesced the potential RyR2 regions to four CaMBDs, here referred to as CaMBD1a, -1b, 
-2 and -3 (Figure 2 and Table 1), but CaMBD2 is the only bona-fide RyR2 CaMBD functionally characterized 
and validated [6-9,12-14,17]. The CaM C-domain binding to CaMBD2 around RyR2 Trp-3587 is a prerequisite 
for CaM-dependent RyR2 inhibition. However, the CaM N-domain can also bind CaMBD2 around Phe-3603, 
albeit the function of the latter interaction is undefined [6-9,15-19]. On the other hand, the functional 
significance of CaMBD1a, -1b or -3 for CaM-dependent RyR2 inhibition remains unknown [5,15,20]. It has 
been proposed that the CaM N-domain shifts between RyR2 binding sites in response to changes in [Ca2+]cyt 
during cardiomyocyte Ca2+ oscillations, and that RyR2 CaMBDs other than CaMBD2 may be involved in this 
process [1,4-13,15,16,21]. Recent cryogenic electron microscopy (cryo-EM) structures of the RyR2-CaM 
complexes support that the CaM N-domain shifts with increasing Ca2+, but not to CaMBD1a, -1b or -3. 
However, Gong et al. and other studies also demonstrate that RyR2-CaM conformations are numerous and 
depend on the ligands present in the channel complex [5,17,22-24]. 
Mutations in CaM cause severe forms of cardiac arrhythmia, most likely due to perturbation of the 
intricate Ca2+ signals required for regulating cardiac excitation and contraction. Of the 15 CaM mutations A
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currently known, 14 are in the CaM C-domain and can cause insufficient RyR2 inhibition, most likely due to 
aberrant interactions among the CaM C-domain, Ca2+ and RyR2 CaMBD2 [8,16,25-37]. However, one CaM 
mutation is located in the N-domain, N54I, and specifically causes catecholaminergic polymorphic ventricular 
tachycardia (CPVT) highly likely due to its diminished inhibition of RyR2. Indeed, CaM-N54I causes 
excessive RyR2 activity in HEK293 cells, isolated cardiomyocytes and of single RyR2 channels, yet CaM-
N54I binds to Ca2+, a RyR2 CaMBD2 peptide, and intact RyR2 channels almost indistinguishably from the 
CaM-WT [8,16,25,27,37-40]. These observations raise an interesting question of whether the CaM N-domain 
interacts with other RyR2 CaMBDs, such as CaMBD1a, -1b or -3, rather than CaMBD2, and that the N54I 
mutation impairs RyR2 inhibition by perturbing such interactions.
In this study, we investigated whether the effects of CaM-N54I on CaM-dependent RyR2 inhibition are 
dependent on RyR2 CaMBD1a, -1b, -2 or -3. Usefully, this also involved investigating the role of the putative 
CaMBD1a, -1b and -3 with respect to native CaM-dependent regulation of RyR2. To this end, we individually 
removed each of the CaMBDs in RyR2 and determined their effects on CaM-dependent inhibition of RyR2-
mediated Ca2+ release in HEK293 cells, both during store-overload induced Ca2+ release (SOICR) in intact 
cells, and in permeabilized cells with a sustained free Ca2+ concentration ([Ca2+]free) of 1 M  [7,8,16,41]. We 
evaluated CaM-dependent RyR2 inhibition by CaM-WT and CaM-N54I. CaM-WT inhibited RyR2 Ca2+ 
release in intact cells despite deleting either CaMBD1a, -1b or -3, while CaM-N54I decreased CaM-dependent 
RyR2 inhibition, compared to CaM-WT. Using permeabilized cells in the presence of 1 M cytosolic [Ca2+]free, 
exogenously added CaM-WT markedly inhibited RyR2 Ca2+ release despite deletion of CaMBD1a, -1b and -3, 
and again CaM-N54I was less effective in inhibiting RyR2 than the CaM-WT. In comparison, deleting 
CaMBD2 ablated the effect of CaM-WT or CaM-N54I on RyR2 inhibition in either assay. We also found that 
CaM-WT inhibited ryanodine binding to RyR2 despite deleting CaMBD1b or -3, and that CaM-N54I in 
comparison failed to inhibit ryanodine binding, regardless of CaMBD deletions. Taken together, we found that 
CaMBD1a is integral to native RyR2 regulation, but only CaMBD2, and not CaMBD1a, -1b or -3, is strictly 
required for CaM-dependent inhibition of RyR2 Ca2+ release under our experimental conditions. Our results 
support the notion that while CaM-N54I requires RyR2 CaMBD2 for its effect, the N54I mutation decreases 
the inhibition of RyR2 via an additional CaMBD that has yet to be identified.
RESULTS
Three-dimensional localizations of known and proposed RyR CaM binding domains (CaMBDs) 
To structurally evaluate the positions of the RyR2 CaMBDs in the homotetrameric channel, we used the 
recently available cryo-EM structures of RyR2 in complex with CaM in the absence and presence of Ca2+ A
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(Figure 1 and Table 1) [17]. Gong et al. show that in the absence of Ca2+ the CaM N-domain binds RyR2 in a 
cleft formed by the handle, helical, and central domains (Figure 1A and -C), although not via the CaM N-
domain’s Met rich binding groove which is critical to the interaction with RyR2 CaMBD2 [4,42]. In the 
absence of Ca2+, the CaM C-domain binds part of RyR2 CaMBD2 around Phe-3603 (Figure 1E) via the C-
domain’s Met rich binding groove. In the presence of Ca2+, the Ca2+-bound CaM C-domain shifts to the C-
terminal part of CaMBD2 (from Phe-3603 to Trp-3587), and the Ca2+-bound CaM N-domain rotates 
approximately 180o about the CaM linker that connects the N- and C-domain, and binds RyR2 CaMBD2 
around Phe-3603 via its Met rich binding groove (Figure 1E-F) [17]. Here we mainly consider CaM’s 
conformational changes, but noteworthy RyR2 also undergoes considerable conformational changes depending 
on the ligands present (Figure 1A-D).
The regions of RyR2 CaMBD2 that interact with CaM are fully resolved in the Ca2+-saturated RyR2-
CaM structure (Lys-3584 to Pro-3607, Figure 1F), but only the C-terminal part is resolved in the absence of 
Ca2+ (Ser-3592 to Pro-3607, Figure 1E). None of the three putative RyR2 CaMBDs are fully resolved in the 
current RyR2 structures, but their approximate locations can be inferred [17,22]. The 13 most N-terminal 
amino acids of RyR2 CaMBD1a are visible (Arg-1941 to Met-1953) and this region directly contacts the CaM 
C-domain, but not the CaM N-domain, in either RyR2-CaM conformation (Figure 1C-D).  Approximately half 
of RyR2 CaMBD1b is resolved (Leu-2029 to Tyr-2038), and the location of CaMBD3 unfortunately remains 
obscure as it is within the Ser-4207 to Ile-4484 unresolved region. No direct contact between the CaM N-
domain and CaMBD1a, -1b or -3 are observed. The cryo-EM structure is of the porcine RyR2, but the 
numbering used here refers to the corresponding human RyR2 amino acids as determined from the sequence 
alignments.
As a further evaluation of the RyR CaMBDs, we performed protein alignments of ryanodine receptor 
type 1-3, and also submitted the RyR2 protein sequence to the CaM-binding site search tool available from the 
CaM target database (CTD) [43]. Multiple protein sequence alignments showed that CaMBD1a and the 
canonical CaMBD2 are located within regions highly conserved between RyR1-3, whereas regions around 
CaMBD1b and especially CaMBD3 show significant differences between RyR isoforms (Figure 2). Moreover, 
RyR2 CaMBD3 is located within a region (Asp3790-Glu4562) previously designated as one of the three so-
called divergent regions among RyR isoforms [5,44]. Analysing the RyR2 protein sequence for CaM-binding 
motifs using the CTD identified CaMBD2 and CaMBD3 as a 1-14-motif and a 1-5-10-motif, respectively [45]. 
In addition, a non-canonical CaM-binding site was identified within the CaMBD1b using a partial RyR2 
sequence, Ala1240-Asn2700. Noteworthy, no CaM-binding site was predicted within RyR2 CaMBD1a.
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The CaM-N54I mutation slightly decreases the binding of CaM to RyR2 CaMBD1a and -1b, but does 
not alter CaM binding to CaMBD2 and -3 peptides
To investigate whether CaM-N54I binding to RyR2 CaMBDs differs from that of the CaM-WT, we 
measured the affinity of CaM-WT and -N54I for binding to peptides representing each of the RyR2 CaMBDs 
(Table 2). Because these interactions are strongly dependent on the free Ca2+ concentration ([Ca2+]free), we 
measured CaM’s affinity for binding to each peptide in a physiologically relevant [Ca2+]free range (~0.05 – 400 
M) [46]. This was done by titrating fluorescently labelled peptides with CaM in [Ca2+]free-buffered solutions 
and monitoring the extent of CaM binding to the peptides using the change in peptide fluorescence anisotropy 
(FA). By fitting these FA titration curves to a stoichiometric binding model, we obtained the affinity of CaM 
for binding to each peptide expressed as that interaction’s dissociation constant (KD) at each [Ca2+]free (Figure 
3) [46].  A low KD equates to extensive protein-peptide complex formation and thus a high-affinity interaction 
(see ‘Materials and methods’).
CaM-WT bound to the CaMBD2 peptide with a high affinity (KD 1.2 nM – 1 M) and the binding was 
strongly Ca2+-dependent from 2 nM to 4 M [Ca2+]free. The KD for the interaction between CaM-WT and the 
CaMBD2 peptide decreased more than 330-fold from 0.05 to 4 M [Ca2+]free and no further decrease in KD  
was observed above 4 M [Ca2+]free. Similarly, CaM-WT also bound to the CaMBD3 peptide in a highly Ca2+-
dependent manner and with more than 1 M [Ca2+]free, Ca-WT’s affinity for binding the CaMBD3 peptide (KD 
< 1 nM) was even higher than that of the CaM-WT-CaMBD2 interaction. The binding of CaM-N54I to the 
CaMBD2 peptide was not significantly different from that observed for CaM-WT at any [Ca2+]free, and this was 
also the case for the CaMBD3 peptide. Binding of CaM-WT to the RyR2 CaMBD1a and -1b peptides was also 
strongly Ca2+-dependent, although binding was only detectable (KD < 2 M) from 0.4 M and 2 M [Ca2+]free, 
respectively (Figure 3). The KD for CaM-WT binding to the RyR2 CaMBD1a peptide decreased 15-fold in the 
[Ca2+]free range from 2 to 400 M, and similarly the KD for CaM-WT binding to the RyR2 CaMBD1b peptide 
decreased 10-fold in the range 0.4 to 400 M [Ca2+]free. Binding of CaM-N54I to the RyR2 CaMBD1a and 
CaMBD1b peptides showed the same Ca2+-dependency as the CaM-WT interaction. However, CaM-N54I had 
a significantly lower affinity for binding either of these RyR2 CaMBD peptides, compared to the CaM-WT 
(Table 3). Beginning at 2 M [Ca2+]free the KD for CaM-N54I binding to the RyR2 CaMBD1a peptide was on 
average 1.4-fold higher than that for the CaM-WT (Figure 3 and Table 3). Similarly, beginning at 2 M 
[Ca2+]free the KD for CaM-N54I binding to the RyR2 CaMBD1b peptide was on average 1.8-fold higher than the 
KD for CaM-WT binding.
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Taken together the results from titrations of RyR2 CaMBD peptides with either CaM-WT or -N54I 
showed that the N-domain N54I mutation slightly decreased CaM’s affinity for binding to RyR2 CaMBD1a 
and -1b, albeit the mutation did not affect binding to RyR2 CaMBD2 or CaMBD3.
CaM-WT, but not CaM-N54I, decreases [3H]ryanodine binding to RyR2 despite deletion of CaMBD1a, -
1b or -3
A hall-mark of RyR2 channels is their binding to the agonist ryanodine [5,47]. Ryanodine binds with 
high affinity to RyR2 channels in their open conformation, and the RyR2-ryanodine association is therefore an 
indirect estimate of RyR2 open propensity [47,48]. To investigate the effect of CaM on this open propensity we 
measured the time-dependent binding of tritium ([3H]) labelled ryanodine to lysates of RyR2-expressing 
HEK293 cells, without or with addition of CaM. Also, to investigate the significance of RyR2 CaMBDs for the 
effect of CaM on RyR2 ryanodine binding, we used the five different HEK293 cell lines expressing RyR2 
variants with each CaMBD deleted (Table 1 and Figure 4). Binding experiments were done at 1 μM [Ca2+]free, 
and with either no added CaM (Ctrl) or addition of either CaM-WT or CaM-N54I (Figure 4A). Binding of 
[3H]ryanodine to RyR2 variants was measured for different time points, and the resulting binding curves were 
fitted to a one-phase association model for determining the ryanodine association rate (K) and the total 
ryanodine binding at near equilibrium (Beq).
Lysates from cells expressing RyR2-WT, -CaMBD2 or -CaMBD3 showed similar equilibrium 
ryanodine binding (average Beq 119 ±12 countsLh-1g-1), comparing reactions without additional CaM (Figure 
4B). On the other hand, the binding curves for lysates with RyR2-CaMBD1a or -CaMBD1b showed an 
approximately 2-fold lower equilibrium ryanodine binding (Beq 32±3 and 53±4 countsLh-1g-1), compared to 
former three RyR2 variants. This difference in the fitted [3H]ryanodine binding at equilibrium indicated that 
RyR2-CaMBD1b and -CaMBD1a bound ryanodine to a lesser extent than the other RyR2 variants at 1 M 
[Ca2+]free. Nevertheless, the effect of CaM on [3H]ryanodine binding could be investigated for all RyR2 variants 
by monitoring changes to the [3H]ryanodine association rate in the absence or presence of CaM.
Addition of CaM-WT to the binding reactions with lysate containing RyR2-WT significantly decreased 
the [3H]ryanodine association rate from 0.9 to 0.6 h-1 while addition of CaM-N54I did not affect the rate of 
binding (K 1.0 h-1), compared to reactions without CaM added (Figure 4C). A tendency towards a slightly 
slower [3H]ryanodine association rate was observed with the addition of CaM-N54I, compared to the Ctrl 
condition, but it was not statistically significant. Results similar to those for RyR2-WT were observed for cell 
lysates containing RyR2-CaMBD1b or -CaMBD3 i.e. addition of CaM-WT markedly decreased the 
[3H]ryanodine association rate while addition of CaM-N54I only tended to decrease the association rate slightly A
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and not significantly. CaM-WT appeared to decrease the [3H]ryanodine association rate more so when added to 
lysates with RyR2-CaMBD3 than when added to RyR2-WT lysates, however this difference in magnitude of 
effect was not statistically significant. For lysates containing RyR2-CaMBD1a, the same tendency for CaM-
WT to decrease the [3H]ryanodine association rate was observed, although the effect was not statistically 
significant. This lack of statistical significance was ascribed to the over-all [3H]ryanodine binding to lysates 
with RyR2-CaMBD1a being too low to adequately resolve potential differences in the binding curves. 
Addition of CaM-WT or -N54I to lysates containing RyR2-CaMBD2 did not significantly affect the 
[3H]ryanodine association rate, compared the reaction with no CaM added. Moreover, no significant 
differences were observed when comparing the [3H]ryanodine association rates between the five different 
RyR2-variants without CaM addition i.e. the CaMBD deletions appeared not to significantly affect the rate of 
[3H]ryanodine at 1 M [Ca2+]free, compared to that for RyR2-WT.
Taken together, these results indicate that CaM-WT decreased [3H]ryanodine binding to RyR2-WT, -
CaMBD1b and -CaMBD3 whereas CaM-N54I did not, or only did so to a much lesser extent. The same 
tendency was observed for RyR2-CaMBD1a, although definitive conclusions could not be made with this 
data set. Neither CaM-WT nor –N54I significantly affected [3H]ryanodine binding to RyR2-CaMBD2.
CaM-N54I diminishes CaM-dependent inhibition of RyR2-mediated store-overload induced Ca2+ release 
in HEK293 cells despite deletion of CaMBD1a, -1b or -3
For a more detailed investigation of the functional effects of the N54I mutation on the CaM-dependent 
inhibition of RyR2 Ca2+ release, with respect to the four CaMBDs, we measured the effect of CaM on store-
overload induced Ca2+ release (SOICR) in HEK293 expressing each of the RyR2 variants (Table 1). To this 
end, we co-transfected RyR2-expressing HEK293 cells with the D1ER Ca2+ probe and either CaM-WT or 
CaM–N54I [7,8,39]. Extracellular perfusion of cells with 2 mM Ca2+ increased the endoplasmic reticulum (ER) 
free Ca2+ concentration (ER Ca2+ load) and caused SOICR such that the ER Ca2+ load oscillated with the 
concerted opening and closing of RyR2 channels (Figure 5). The activation threshold (ER Ca2+ load at SOICR 
initiation) and the termination threshold (the ER Ca2+ load at which Ca2+ release ceases) were determined from 
the oscillations in the D1ER probe’s fluorescence resonance energy transfer (FRET) signal, and the difference 
(activation threshold – termination threshold) was the fractional ER Ca2+ release (Figure 5A) [7,41]  – please 
see [39] for a graphical overview of the process. An increase in the activation threshold indicates that RyR2 
channels are less sensitive to stimulation by ER luminal Ca2+, and similarly an increase in the termination 
threshold indicates that channels are more susceptible to inactivation when open. Thus, increases in the RyR2 A
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activation and/or termination thresholds indicate inhibition of RyR2 Ca2+ release, and accordingly so does a 
decrease in the fractional ER Ca2+ release.
The SOICR experiments were carried out with three different CaM conditions: control (i.e. only 
endogenous CaM), CaM-WT or CaM–N54I plasmid-mediated expression in each of the five different cell lines 
expressing either RyR2-WT, -CaMBD1a, -CaMBD1b, -CaMBD2 or -CaMBD3 (Figure 5 and Table 1). 
HEK293 cells endogenously express CaM, but transfecting HEK293 cells with a CaM expression plasmid 
increases the CaM protein level and thereby affects the CaM-dependent inhibition of RyR2 during SOICR (see 
Figure 10 in ‘Materials and methods’). Transfection with a CaM-WT plasmid increases the observed RyR2 
termination threshold whereas transfection with a CaM-N54I plasmid decreases both the activation and 
termination threshold, thereby markedly reducing CaM’s inhibition of RyR2. Noteworthy, RyR2-CaMBD2 is 
insensitive to the CaM expression conditions, which is consistent with the ablation of CaM-dependent RyR2 
inhibition [7,8,16,39].
In this study, exogenous CaM-WT expression facilitated the inhibition of RyR2-WT by increasing the 
termination threshold 4 % (from 58 to 62 %), compared to the control, and thereby reduced the fractional ER 
Ca2+ release from 31 to 29 % (Figure 6B-C, Table 4). Conversely, CaM-N54I expression diminished RyR2-WT 
inhibition and increased fractional ER Ca2+ release (from 29 to 36 %) by lowering both the activation (from 90 
to 85 %) and termination threshold (from 62 to 49 %), compared to CaM-WT expression (Figure 6A-C, Table 
4). Although subtle, the inhibitory effect of CaM-WT expression on RyR2 Ca2+ release is consistently observed 
during SOICR in RyR2-expressing HEK293 cells [7,8,16,39]. The small but significant changes by 
exogenously expressed CaM-WT most likely reflect a greater saturation of RyR2 with CaM, thereby increasing 
the inhibition of RyR2 already exerted by endogenous CaM. In the same way, the expressed CaM-N54I can 
bind to unoccupied RyR2 CaMBD sites, and likely also to some extent replaces endogenous CaM-WT due to 
mutant protein abundance [7,8,16,39]. Plasmid expression of CaM-WT or CaM-N54I increased total CaM 
protein levels 2-fold in HEK293 cells, compared to endogenous CaM expression (see ‘Materials and 
methods’).
Compared to RyR2-WT, RyR2-CaMBD1a showed a markedly increased activation threshold and this 
was true for all CaM expression conditions (Figure 6A, Table 4). Moreover, with only endogenous CaM (Ctrl) 
the termination threshold for RyR2-CaMBD1a was clearly decreased compared to RyR2-WT (36 vs 58 %, 
Figure 6B). Because RyR2-CaMBD1a had both an increased activation and a decreased termination 
threshold, the resulting fractional ER Ca2+ release increased 2-fold from 31 to 61 %, comparing the controls for 
RyR2-WT and RyR2-CaMBD1a (Figure 6C). Remarkably, CaM-WT expression nearly rescued this 
excessive RyR2-CaMBD1a Ca2+ release by prominently increasing the RyR2-CaMBD1a termination A
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threshold from 36 to 57 %, compared to the control (Figure 6B-C). Compared to the effect of CaM-WT, CaM-
N54I expression markedly decreased the termination threshold (from 57 to 42 %) and therefore increased the 
fractional ER Ca2+ release from 44 to 55 % (Figure 6A-C). 
Unlike the observations made with RyR2-CaMBD1a, the effects of deleting CaMBD1b were subtle 
although RyR2-CaMBD1b showed a decreased activation threshold, compared to RyR2-WT, both with and 
without CaM expression (~ 84 vs. 90 %, Figure 6A). Compared to the control condition, CaM-WT expression 
increased the RyR2-CaMBD1b termination threshold (63 vs. 58 %), and thereby minutely lowered the 
fractional ER Ca2+ release (22 vs 25 %). These effects of CaM-WT expression where highly similar to the 
effects of CaM-WT expression on RyR2-WT (Figure 6B-C), and similarly CaM-N54I expression also 
decreased the RyR2-CaMBD1b termination threshold from 63 to 53 %, compared to CaM-WT expression. 
On the other hand, CaM-N54I expression did not significantly lower the RyR2-CaMBD1b activation 
threshold as it did for RyR2-WT.
Interestingly, the inherent effects on the RyR2 activation threshold stemming from deleting either 
CaMBD1a (marked activation increase) or CaMBD1b (subtle activation decrease) appeared to occlude any 
further effects of CaM-N54I expression on the activation thresholds of either RyR2-CaMBD1a or -
CaMBD1b. However, a tendency towards a slightly lowered activation threshold from CaM-N54I expression 
was observed for RyR2-CaMBD1a and -CaMBD1b, compared to CaM-WT expression.
RyR2-CaMBD3 did not show any significant differences in the RyR2 Ca2+ release properties during 
SOICR, compared to RyR2-WT. Moreover, CaM-WT and CaM-N54I expression affected RyR2-CaMBD3 
the same as RyR2-WT (Figure 6A-C, Table 4). Collectively, the deletion of either CaMBD1a, -1b or -3 did not 
diminish the effect of either CaM-WT or CaM-N54I expression on RyR2 regulation during SOICR 
oscillations: CaM-WT expression increased CaM-dependent inhibition of RyR2 Ca2+ release, whereas CaM-
N54I diminished RyR2 inhibition.
CaM-N54I diminishes CaM-dependent inhibition of RyR2-mediated Ca2+ release in permeabilized 
HEK293 cells with elevated cytosolic Ca2+, despite deletion of CaMBD1a, -1b or -3
Ca2+ binding to CaM increases its inhibitory effect on RyR2, and most likely more than 1 M [Ca2+]cyt is 
required to fully saturate CaM with Ca2+ during its interaction with RyR2 [8,16]. During SOICR in HEK293 
cells, [Ca2+]cyt oscillates between approximately 0.05 – 2 M i.e. only briefly reaches 1 M [49,50] (time trace 
nadirs, Figure 5). To better investigate CaM-dependent RyR2 inhibition under elevated [Ca2+]cyt, conditions, we 
used permeabilized HEK293 cells and a Ca2+-buffered perfusion medium with a constant 1 M [Ca2+]free. A
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Cytosolic 1 M [Ca2+]free strongly activates RyR2 and consequently reduces the ER Ca2+ load required for 
triggering SOICR, i.e. lowers the activation threshold. Under such conditions, RyR2 Ca2+ release does not 
cause oscillations in ER Ca2+ concentrations, but instead the ER Ca2+ load reaches a steady-state that likely 
reflects the opposing fluxes of RyR2 Ca2+ release and the SR/ER Ca2+ ATPase 2 (SERCA2b) Ca2+ uptake [51]  
– please see [39] for a graphical overview of the process. The D1ER Ca2+ probe FRET signal can then be used 
for measuring this steady-state ER Ca2+ load at a given perfusion condition (Figure 7) [39,52].
To measure the effect of CaM on RyR2 Ca2+ release, the steady-state ER Ca2+ load in permeabilized 
HEK293 cells expressing each of the RyR2 variants was measured first without CaM (endogenous CaM 
washed out) and then after the addition of either CaM-WT or -N54I (Figure 7, Figure 8 and Table 5). The 
removal of endogenous CaM during permeabilization was evident from the steady-state ER Ca2+ load for 
RyR2-WT and RyR2-CaMBD2 (that abolishes CaM-dependent inhibition) being the same before the addition 
of CaM-WT (Figure 8 and Table 5), and also from the marked response of RyR2-WT to exogenous CaM 
addition.
Addition of exogenous CaM-WT to permeabilized cells expressing RyR2-WT increased the steady-state 
ER Ca2+ load 1.3-fold from 32 to 41 %, i.e. reduced ER Ca2+ release by inhibiting RyR2. Conversely, addition 
of CaM-N54I decreased the steady-state ER Ca2+ load 0.9-fold from 32 to 27 % and thus had the opposite 
effect compared to the addition of CaM-WT. In other words, CaM-N54I not only failed to inhibit but also 
facilitated RyR2-mediated Ca2+ release as evident from the steady-state ER Ca2+ with CaM-N54I being 
significantly below that observed without any CaM present. The observed facilitation of RyR2 Ca2+ release by 
CaM-N54I was similar to previous observations made for arrhythmogenic CaM C-domain mutations, although 
considerably smaller in magnitude [39,52]. In contrast to RyR2-WT, no significant effect on steady-state ER 
Ca2+ load was observed when adding CaM-WT to RyR2-CaMBD2, and RyR2-CaMBD2 has also previously 
been shown to be insensitive to regulation by CaM-N54I as well as other CaM mutants [7,8,39]. This result 
strongly supported that the effects of adding CaM-WT or -N54I to RyR2-WT were due to CaM regulating 
RyR2, and not secondary effects due to CaM affecting other protein targets.
The effect on steady-state ER Ca2+ load from adding CaM-WT to RyR2-CaMBD1b or -CaMBD3 
expressing cells were not significantly different from the effect of adding CaM-WT to cells expressing RyR2-
WT (group b, Figure 8A-B). Moreover, adding CaM-N54I to cells expressing RyR2-CaMBD1b or -
CaMBD3 caused decreases in the steady-state ER Ca2+ load which were indistinguishable from the effects of 
adding CaM-N54I to RyR2-WT expressing cells (group c, Figure 8A-B). Hence, deleting RyR2 CaMBD1b or 
CaMBD3 did not significantly affect the native CaM-dependent inhibition of RyR2-mediated Ca2+ release at 1 
M cytosolic Ca2+, nor did these deletions impede CaM-N54I in promoting RyR2 Ca2+ release.A
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The effects of adding CaM-WT or -N54I to cells expressing RyR2-CaMBD1a were more complex 
(group d and *, Figure 8A-B). Addition of CaM-WT increased the steady-state ER Ca2+ load 1.7-fold from 31 
to 54 %, and this was significantly greater than the 1.3-fold increase observed when adding CaM-WT to RyR-
WT. In fact, the quantified increase caused by CaM-WT on the steady-state ER Ca2+ load in cells expressing 
RyR2-CaMBD1a (21 %) was approximately double that observed with RyR2-WT (9.1 %). Interestingly, 
addition of CaM-N54I to RyR2-CaMBD1a expressing cells did not decrease the steady-state ER Ca2+ load as 
observed for cells expressing RyR2-WT, -CaMBD 1b and -CaMBD3. Instead, CaM-N54I addition 
increased the steady-state ER Ca2+ load in cells expressing RyR2-CaMBD1a 1.3-fold from 31 to 41 %, 
noteworthy this was a significantly smaller increase than conferred by the CaM-WT acting on RyR2-
CaMBD1a. At the same time this effect of CaM-N54I on the steady-state ER Ca2+ load was distinct from its 
effect on all other RyR2 expressing cells. However, given the inherent effect of CaMBD1a deletion on RyR2 
activity (Figure 4B) and that RyR2-CaMBD1a appeared more susceptible for regulation by CaM (Figure 6), the 
main observation was that CaM-N54I still caused less inhibition of RyR2 than CaM-WT.
Taken together these results showed that CaM-WT strongly inhibited ER Ca2+ release in permeabilized 
cells expressing RyR2-WT, whereas CaM-N54I promoted ER Ca2+ release. Noteworthy, removing RyR2 
CaMBD1b or CaMBD3 did not significantly change the effects on RyR2-mediated ER Ca2+ release conferred 
by CaM-WT or CaM-N54I. Deleting RyR2 CaMBD1a, however, increased the magnitude of the RyR2 
inhibition conferred by CaM-WT two folds and caused CaM-N54I to exert a net inhibitory effect, although still 
less than the CaM-WT effect.
Deletion of CaMBD1a, CaMBD1b or CaMBD2 affects the response of RyR2 to caffeine activation
Results so far indicated that the deletions of CaMBD1a and to a lesser extent CaMBD1b inherently 
affected RyR2 ryanodine binding and Ca2+ release in our experiments. To further investigate the impact of 
RyR2 CaMBD deletions on channel function, we measured the response of each RyR2 variant to activation by 
caffeine through monitoring the bulk, cytosolic Ca2+ transients in HEK293 cells resulting from successive 
addition of caffeine. RyR2-mediated ER Ca2+ release strongly depends on the concentrations of ER luminal 
Ca2+, and caffeine increases RyR2 propensity for activation by ER luminal Ca2+. Thus, for each increase in 
caffeine concentration, the threshold for RyR2 activation by ER Ca2+ is lowered and Ca2+ is released into the 
cytosol until ER luminal Ca2+ again becomes lower than that needed for opening RyR2. Also, HEK293 cells 
maintain cytosolic Ca2+ homeostasis such that ER Ca2+ released is eventually cleared, and altogether this 
process results in a transient, cytosolic Ca2+ increase (peak) for each caffeine addition (Figure 9A). These peaks A
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were monitored using a cytoplasmic, fluorescent Ca2+ probe (Fluo-3), and peak the height as a function of 
cumulative caffeine concentration gave a caffeine response profile for each RyR2 variant (Figure 9B).
The caffeine response profiles showed that all RyR2 variants were sensitive to caffeine stimulation, and 
that the deletion of either CaMBD1a, CaMBD1b or CaMBD2 did affect RyR2’s response to caffeine (Figure 
9B). A leftward-shift in the profile of the caffeine-induced Ca2+ release for RyR2-CaMBD1b, i.e. more of the 
ER-stored Ca2+ released at lower cumulative caffeine concentration, indicated an increased caffeine response 
compared to RyR2-WT. Conversely, a rightward-shift in the profile for RyR2-CaMBD1a showed that this 
deletion mutant was less responsive to caffeine stimulation than RyR2-WT. Similarly, the RyR2-CaMBD2 
showed to have a slightly reduced sensitivity to caffeine specifically at high cumulative concentrations (> 1 
mM). Finally, RyR2-CaMBD3 channels displayed a response to caffeine indistinguishable from that of the 
RyR2-WT channels.
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DISCUSSION
CaM is a central regulator of intracellular Ca2+ release and excitation-contraction coupling in cardiac 
cells, and mutations in CaM cause severe arrhythmias [4,20,53]. One erroneous regulation caused by the CaM 
mutations is a diminished CaM-dependent inhibition of RyR2-mediated Ca2+ release from the ER/SR Ca2+ 
store [4,8,16,20,27,31,39,40,53,54]. Our current model for the CaM-RyR2 interaction is that under 
cardiomyocyte resting conditions (~100 nM [Ca2+]cyt), the CaM C-domain is nearly saturated with Ca2+ and 
constitutively anchored to CaMBD2 around Trp-3587 whereas the CaM N-domain is not bound to Ca2+ or 
CaMBD2 and may interact with other RyR2 CaMBDs. Upon cardiomyocyte excitation the CaM N-domain 
binds Ca2+ as [Ca2+]cyt increases and this changes its interaction with RyR2 CaMBDs, and with one possibility 
being that the Ca2+-saturated CaM N-domain binds to RyR2 CaMBD2 around Phe-3603, as observed in cryo-
EM structures with Ca2+ present [7,8,16-19,39,46]. Structures in the physiological resting state (closed RyR2 
and only the CaM C-domain Ca2+-loaded) are not available, and the effect of the CaM C-domain’s shift from 
Phe-3607 to Trp-3587 on the Ca2+-free CaM N-domain remains unknown. Moreover, none of the three putative 
RyR2 CaMBDs are fully resolved in the current structures. Noteworthy, cryo-EM studies represent a subset of 
possible RyR2 macro complex conformations, and also clearly demonstrate that these conformations shift 
considerably depending on the ligands present [5,17,22-24]. Thus, interactions between CaM and CaMBD1a, -
1b or even -3 cannot be completely ruled out.
Disruption of the tripartite interaction between Ca2+, the CaM C-domain and RyR2 CaMBD2 leads to 
excessive Ca2+ release which can cause arrhythmia or cardiomyopathy, and this likely explains the diminished 
RyR2 inhibition conferred by CaM C-domain mutations [7-9,11-13,16,39,53,55,56]. However, the CaM-N54I 
mutation is the only N-domain mutation of the fifteen known CaM mutations and seemingly has little or no 
effect on CaM interaction with CaMBD2 or CaM binding to Ca2+ [8,16,25,38-40,54], yet it markedly impairs 
CaM-dependent inhibition of RyR2 [8,16,25,27,34,38,40,57].
In this study we investigated whether an interaction between the CaM N-domain and RyR2 CaMBD1a, 
CaMBD1b or CaMBD3 may explain the diminished CaM-dependent RyR2 inhibition conferred by CaM-N54I. 
Simultaneously, this study also assessed the functional significance of the RyR2 CaMBDs in the regulation of 
RyR2 by CaM-WT [7,8,16,41]. To this end we expressed RyR2-WT and four deletion mutants with the RyR2 
CaMBD1a, CaMBD1b, CaMBD2 or CaMBD3 removed (Table 1) and investigated the effect of both CaM-WT 
and CaM-N54I on the CaM-dependent inhibition of RyR2. In the protein-peptide binding assay, CaM-N54I 
had a significantly lower Ca2+-dependent affinity for binding to the CaMBD1a and CaMBD1b peptides, but the 
same affinity for binding to the CaMBD2 or CaMBD3 peptides, compared to the CaM-WT. This indicated that 
the N54I mutation may affect the interaction between RyR2 CaMBD1a and CaMBD1b and the CaM N-domain A
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(Figure 3 and Table 3). Also, since both CaM-WT and CaM-N54I readily bound to RyR2 CaMBD1a, 
CaMBD1b and CaMBD3 peptides, these regions were expected to be relevant for CaM-dependent RyR2 
regulation for both CaM variants. However, our experiments using SOICR in intact HEK293 cells showed that 
CaM-N54I conferred insufficient RyR2 inhibition during SOICR, compared to CaM-WT, despite deletions of 
either CaMBD1a, -1b or -3. Moreover, CaM-WT expression increased the inhibition of RyR2 Ca2+ release 
regardless of removing either CaMBD1a, -1b or -3 (Figure 6 and Table 4). Similarly, in experiments using 
permeabilized HEK293 cells with sustained 1 M cytosolic side [Ca2+]free, addition of purified CaM-WT 
inhibited RyR2 Ca2+ release and CaM-N54I caused significantly less inhibition, despite deletion of either 
CaMBD1a, -1b or -3 (Figure 8 and Table 5). The apparent lack of effect of CaMBD deletions on CaM-
dependent RyR2 inhibition was consistent with the lack of effect of CaMBD deletions on CaM-mediated 
decrease in [3H]ryanodine binding to RyR2 (Figure 4).
Interestingly, CaM-N54I addition even promoted RyR2 Ca2+ release in permeabilised cells expressing 
RyR2-WT, -CaMBD1b and -CaMBD3, an effect previously observed for some CaM C-domain mutations 
[39]. The N54I mutation did not promote Ca2+ release in permeabilized cells expressing RyR2-CaMBD1a but 
still decreased RyR2 inhibition, compared to CaM-WT. Therefore CaM-N54I appeared to diminish RyR2 
inhibition less so in cells expressing RyR2-CaMBD1a, compared to RyR2-WT, -CaMBD1b and -CaMBD3. 
If removing CaMBD1a disrupted a RyR2-CaM N-domain interaction, CaM-WT and CaM-N54I should affect 
RyR2-CaMBD1a similarly, but oppositely we found that the N54I mutation still diminished RyR2 inhibition, 
compared to CaM-WT. Thus, the difference in CaM-N54I’s effect on RyR2-CaMBD1a, compared to RyR2-
WT, -CaMBD1b and -CaMBD3, in permeabilised cells was instead considered a consequence of the 
CaMBD1a deletion itself (further details below). 
Although CaMBD1a and CaMBD1b were not a requirement for CaM to inhibit RyR2, deleting either of 
these CaMBDs in itself altered RyR2 Ca2+ release. Removing CaMBD1a markedly reduced RyR2 activation by 
both SOICR and caffeine while simultaneously increasing ER Ca2+ release in intact cells by delaying channel 
closing, i.e. lowered the termination threshold (Figure 9B and Figure 6A-B). In other words, RyR2-
CaMBD1a appeared more resistant to activation than RyR2-WT, yet more prone to increased Ca2+ release 
once opened. This suggests that the region around RyR2 CaMBD1a, and by extension the CaM binding region 
around CaMBD2 (Figure 1), may play a role in RyR2 transitioning between open and closed conformations. 
This is further supported by studies comparing RyR cryo-EM structures, and that RyR2 CaMBD1a interacts 
directly with the CaMBD2-bound CaM C-domain in RyR2-CaM structures [5,17,23]. The inhibitory effect of 
CaM-WT or CaM-N54I on RyR2-CaMBD1a (21 % and 15 %) appeared much greater than their effects on 
RyR2-WT (9.1 % and -3.7 %) in permeabilized cells with 1 M cytosolic [Ca2+]free (Figure 8B). The A
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explanation for this observation is unknown, but we speculate that the decreased sensitivity of RyR2-
CaMBD1a for activation possibly allows a stronger CaM-mediated inhibition due to less contending RyR2 
Ca2+ stimulation. Removing CaMBD1b promoted RyR2 activation as seen from the decreased SOICR 
activation threshold and the increased sensitivity to caffeine (Figure 9B and Figure 6A-B). However, these 
effects were subtle compared to removing CaMBD1a, and there was no significant effect of removing 
CaMBD1b on steady-state ER Ca2+ load in permeabilized cells (Figure 8B).
In summary, we find that under our experimental conditions neither CaMBD1a, -1b nor -3 are strictly 
necessary for CaM-dependent RyR2 inhibition and comparing the effect of CaM-WT to that of CaM-N54I 
there are no significant indications that the CaM N-domain interacts with CaMBD1a, CaMBD1b or CaMBD3. 
I.e. a CaM N-domain interaction with either CaMBDa1, CaMBD1b or CaMBD3 is not the underlying 
mechanism for CaM-N54I’s aberrant regulation of RyR2. Interestingly, our results indicate that CaM primarily 
regulates RyR2 via CaMBD2 or regions other than CaMBD1a, -1b and -3, but also support that CaMBD1a is 
integral to RyR2 regulation possibly through allosteric modulation of CaM binding. The results presented here 
and in previous studies show that RyR2 CaMBD2 is indeed required for CaM-N54I to interact with RyR2 via 
the CaM C-domain, but it is unlikely that the N-domain N54I mutation confers erroneous RyR2 regulation via 
CaMBD2 because the N54I mutation does not affect the CaM-RyR2 CaMBD2 interaction [8,16,25]. Thus, 
given that RyR2 CaMBD1a, -1b or -3 are not strictly required for CaM-dependent regulation of RyR2, and that 
CaM-N54I interacts with Ca2+ and RyR2-CaMBD2 indistinguishably from the CaM-WT, we propose that the 
N54I mutation impairs CaM-dependent RyR2 inhibition through an unknown CaMBD. CaM-N54I’s 
diminished inhibition of RyR2 persisted even in the presence of Ca2+ (Figure 4 and Figure 8) [8,16,40,57], and 
therefore the newly identified region in the RyR2-CaM structure in the absence of Ca2+ that interacts with the 
CaM-N-domain  was not considered a good candidate for this unknown CaMBD. Notable, the molecular 
details of how the N54I mutation diminishes CaM-dependent RyR2 inhibition still remain elusive, and 
therefore a so-far unobserved perturbation of the CaM-RyR2 CaMBD2 interaction cannot be entirely ruled out, 
even though the currently available data does not support this.
To our knowledge this study is the first to investigate the functional significance of RyR2 CaMBDs, 
other than CaMBD2, using intact RyR2 channels and in vivo ER Ca2+ release [5,15,46]. The RyR2-expressing 
HEK293 cells approximate diastole- and early systole-like Ca2+ conditions in cardiomyocytes, and has 
repeatedly proven a valid model for investigating perturbations of intracellular Ca2+ signalling [41,58-62]. 
Thus, this study supports that CaMBD1a, CaMBD1b and CaMBD3 are not required for CaM’s inhibition of 
RyR2 Ca2+ release at low cytosolic Ca2+ levels. However, it is still possible that CaMBD1a, -1b and -3 
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contribute to CaM-dependent RyR2 regulation under certain conditions and [Ca2+]cyt not obtainable in HEK293 
cells, although this remains to be investigated.
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MATERIALS AND METHODS
Ryanodine receptor protein sequence alignment
For protein sequence alignment, fifteen RyR sequences from human, mouse and rabbit RyR1-3, chicken 
RyR2-3, zebrafish RyR1b, C. elegans RyR, D. melanogaster RyR and O. dioica RyR were aligned using the 
ClustalW algorithm in CLC Main Workbench 6 (CLC Bio, version 6.9.1) [63]. UniprotKB file accession 
numbers: P21817, Q92736, Q15413, E9PZQ0, E9Q401, A2AGL3, P11716, P30957, Q9TS33, F1NLZ9, 
Q90985, A6P4B8, P91905, Q24498, E4XPI8. Delimitation of the protein regions corresponding to 
CaMBD1a, CaMBD1b, CaMBD2 and CaMBD3 were adopted from previous studies [9,15,46,64,65]. For 
further evaluation of the four CaMBDs, the human RyR2 protein sequence was submitted to binding site search 
tool which is part of the CaM Target Database [43]. Using this analysis tool, high scoring hits for CaM-binding 
motifs, like those in CaMBD2 and -3, may mask less prominent motifs. Therefore, a partial sequence of human 
RyR2 (Ala1240-Asn2700) was separately submitted to the analysis tool for the detailed analysis of CaMBD1a 
and -1b.
Plasmids and mutagenesis
The pcDNA3.1 (Thermo Fisher Scientific, Waltham, MA, USA ) plasmids with CaM or CaM-N54I 
cDNA inserts for CaM expression in HEK293 cells [8], and the pcDNA3 (Thermo Fisher Scientific ) plasmid 
encoding the D1ER Ca2+ probe have been described previously [7,41,66]. pMAL plasmids (New England 
Biolabs, Ipswich, MA, USA) used for expression of CaM variants in E. coli were described previously [25].
The construction of a pBluescript (Agilent, Santa Clara, California, USA) plasmid carrying mouse RyR2 
cDNA has been described previously [67]. RyR2-WT and a variant with CaMBD2 deleted (RyR2-CaMBD2) 
were available from previous studies [7,8], and for this study we made three novel RyR2 variants (RyR2-
CaMBD1a, -CaMBD1b and -CaMBD3). This was done using overlap-extension PCR to remove from the 
pcDNA3-RyR2 plasmid, the nucleotide sequences corresponding to the protein regions outlined in Table 1, as 
previously described [68,69]. Briefly, a NruI/EcoRV fragment containing CaMBD1a or CaMBD1b was 
generated by overlapping PCR. This fragment was then used to replace the corresponding WT fragment in the 
NheI/BsiwI fragment in pBluescript. The DNA fragment containing the deletion was then subcloned into the 
full-length mRyR2 in pcDNA5/FRT/TO (Thermo Fisher Scientific) using NheI and BsiWI. An MluI/Bsu36I 
fragment containing CaMBD3 was also generated using the overlap PCR. These fragments were used to 
replace the corresponding WT fragment in the BsiwI/NotI fragment of RyR2 in pBluescript. The BsiwI/NotI 
fragment containing the CaMBD3 deletion was used to replace the corresponding WT fragment in the full-
length mRyR2 in pcDNA5/FRT/TO. All deletions were confirmed by DNA sequencing. A
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Protein Expression and Purification
CaM-WT and -N54I were expressed from pMAL in E. coli Rosetta B cells (Merck, Darmstadt, Hesse, 
Germany) and purified as previously described [8,15,25]. The identity, purity, and integrity of each protein 
preparation were confirmed by SDS-PAGE and MALDI-TOF mass spectrometry of trypsin digested proteins. 
Protein concentrations were measured using absorption at 280 nm (extinction coefficient 2560 cm-1M-1).
Peptides corresponding to RyR2 CaMBDs
Peptides with an N-terminal 5-TAMRA (5-carboxytetramethylrhodamine) label and corresponding to 
RyR2 CaMBDs were from Proteogenix (Schiltigheim, France) at > 95 % purity (Table 2). Peptide 
concentrations were determined from the 5-TAMRA absorption at 556 nm (extinction coefficient 103.000 cm-
1M-1). Stock solutions (~600 µM) were kept in 5 % acetonitrile and 0.1 % trifluoroacetic acid.
pH- and Ca2+-buffered solutions
pH- and Ca2+-buffered solutions (pCa-buffer) were prepared as previously described [39,70], and 
contained 50 mM HEPES, 100 mM KCl, 0.3 mM tris(2-carboxyethyl)phosphine, 0.5 mM ethylene glycol-
bis(2-aminoethylether)-tetraacetic acid (EGTA), 1 mM free Mg2+ and 2 mM nitrilotriacetic acid (NTA) at pH 
7.2 (25 oC) with variable concentrations of CaCl2. Mixing various amounts of the pCa-buffers with and without 
3 mM CaCl2 to different [Ca2+]tot established defined EGTA/NTA-buffered [Ca2+]free [70]. The calculated buffer 
ionic strength was 156 mM, and the [Ca2+]free was verified using the Ca2+ probe Fura-2 (Thermo Fisher 
Scientific) and binding of Ca2+ to free CaM [8,46,70].
Titrations of CaMBD peptides with CaM at discrete Ca2+ concentrations
A two-dimensional titration assay was used to determine the affinity of CaM for binding to the RyR2 
CaMBD peptides at 16 discrete [Ca2+]free as previously described [39,46]. Briefly; The binding of CaM to 
peptides was monitored as the change in the fluorescence anisotropy (FA) signal from the TAMRA-labelled 
peptides, and the titrations were done in 384-well microtiter plates (#3575, Corning, New York, NY, USA ) with 
the peptide concentrations kept constant (~50 nM) and varying the CaM concentration. Using the pCa-buffers 
(see above) allowed for mixing high and low [Ca2+]tot solutions to obtain specific [Ca2+]free [70]. Each microtiter 
plate contained 24 titration points (CaM to peptide ratios) at each of the 16 different [Ca2+]free (24 columns by 
16 rows). CaM concentrations covered the range 0.2 nM – 18 µM, and [Ca2+]free the range 0.3 nM – 400 µM. 
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Immediately after mixing, the FA signal was measured in a fluorescence plate reader (Infinite M1000, Tecan, 
Zurich, Switzerland). Mixings and FA measurements were done in triplicates at 25°C.
Titration curve analysis for determining the affinity of CaM for binding to CaMBD peptides
CaM binds RyR2 CaMBD peptides (P) stoichiometrically [15] with the binding affinity expressed as the 
apparent CaM/CaMBD complex (PCaM) dissociation constant (KD) i.e.
𝑃𝐶𝑎𝑀⇆𝑃 + 𝐶𝑎𝑀
𝐾𝐷 =
[𝑃] ∙ [𝐶𝑎𝑀]
[𝑃𝐶𝑎𝑀]
where [P], [CaM] and [PCaM] are the concentrations of free CaMBD, free CaM, and CaM/CaMBD complex, 
respectively. This simple binding model assumes one type of CaM-CaMBD interaction i.e. characterized by 
one KD, and the fractional saturation (Y) of CaMBD with CaM is then
 (1)𝑌 =
[𝑃𝐶𝑎𝑀]
[𝑃]𝑡𝑜𝑡 =
𝐾𝐷 + [𝑃]𝑡𝑜𝑡 + [𝐶𝑎𝑀]𝑡𝑜𝑡
2 ∙ [𝑃]𝑡𝑜𝑡 ― (𝐾𝐷 + [𝑃]𝑡𝑜𝑡 + [𝐶𝑎𝑀]𝑡𝑜𝑡2 ∙ [𝑃]𝑡𝑜𝑡 )
2
―
[𝐶𝑎𝑀]𝑡𝑜𝑡
[𝑃]𝑡𝑜𝑡
where [P]tot and [CaM]tot are the total concentrations of CaMBD peptide and CaM, respectively. For each plate 
row a titration curve of FA as a function of [CaM]tot was obtained. The measured FA signal consists of the FA 
signal from the free CaMBD peptide (FAP) and the FA signal from the CaM/CaMBD complex (FAPCaM), hence
 (2)𝐹𝐴 = 𝐹𝐴𝑃 ∙ (1 ― 𝑌) + 𝐹𝐴𝑃𝐶𝑎𝑀 ∙ 𝑌
where FAP and FAPCaM represent the minimum (entirely free CaMBD peptide) and maximum (entirely bound 
CaMBD peptide) FA signal. Substituting the expression for Y in equation 1 for Y in equation 2 allowed for 
fitting the binding model to each titration curve and thus obtaining a KD at that [Ca2+]free. The method allows 
reliable fitting of KD values in the approximate range 1 nM – 2 M [46].
CaM binding to RyR2 CaMBD1a does not fit the model in equation 1, but rather a stochiometric interaction 
with two different modes of CaM binding to CaMBD1a, a high affinity and a low affinity, each characterized 
by their own KD (KDI and KDII) [46], and where Y is defined as
(3)𝑌 = ( [𝐶𝑎𝑀]𝐾𝐷𝐼 + [𝐶𝑎𝑀] + [𝐶𝑎𝑀]𝐾𝐷𝐼𝐼 + [𝐶𝑎𝑀])
For low affinity interactions [CaM] ≈ [CaM]tot is a good approximation, and model fitting for CaMBD1a 
was done with this alternate expression for Y in equation 2. We considered only the first mode of CaM-
CaMBD1a interaction with the highest affinity (i.e. KDI). KD (or KDI) as a function of [Ca2+]free was obtained by 
fitting each row-wise titration curve using non-linear regression in GraphPad Prism 6.07. Differences in the 
fitted KD or KDI values for CaM-WT compared to CaM-N54I were evaluated using multiple (one for each 
[Ca2+]free) unpaired t-tests with Holm-Sidak correction for multiple comparisons (p < 0.05 considered A
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significant). For statistically significant differences, the change in standard (1 M and 25 oC) Gibb’s free energy 
of binding (Go) was calculated as
ΔΔ𝐺𝑜 = ―𝑅 ∙ 𝑇 ∙ ln ( 𝐾𝐷, 𝐶𝑎𝑀 ― 𝑊𝑇𝐾𝐷, 𝐶𝑎𝑀 ― 𝑁54𝐼)
Generation of stable and inducible HEK293 cell lines
Genomic modified and inducible HEK293 cell lines for expressing mouse RyR2 and variants were 
generated using the Flp-In T-REx Core Kit (Thermo Fisher Scientific) as previously described [7]. This 
recombinase mediated approach integrates the RyR2 cDNA under control of a tetracycline inducible promoter 
into the flpase recognition target site in the HEK293 Flp-In cell line genome.
[3H]ryanodine binding to RyR2 in HEK293 cell lysates
HEK293 cell lysates were prepared from cell lines induced to express the RyR2 variants as previously 
described [71], and total protein content estimated using the Protein Assay (BioRad, Hercules, California, 
USA). [3H]ryanodine binding at 1 μM [Ca2+]free was done using 0.5-0.8 g/L total protein from cell lysate in 
binding buffer (350 mM KCl, 25 mM Tris, 50 mM HEPES, 5 nM [3H]ryanodine, 2.5 mM DTT, 0.5 mM 
EGTA, 0.47 mM CaCl2 with protease inhibitors including 2.5 mM DTT, pH 7.4). The reaction time was varied 
by spacing additions of [3H]ryanodine to otherwise pre-mixed samples. All reactions were then stopped 
together, and bound [3H]ryanodine was quantified using liquid scintillation counting as previously described 
[71]. Background [3H]ryanodine binding - corresponding to reaction time 0 h - was measured using the 
addition of 50 μM unlabelled ryanodine. Binding curves with four time points were done for each RyR2 
variant, and both without and with the addition of either 7.5 μM purified CaM-WT or -N54I. The measured 
[3H]-activity was normalized to the lysate total protein concentration, and four replicates for each combination 
of RyR2 and CaM conditions were done. The resulting binding curves were fitted to a one-phase association 
reaction (Figure 4A)
Y(t) = Y(0) + 𝐵eq ∙ (1 ― e ―K ∙ t)
, where Y is the measured [3H]-activity, K is the association rate, and Beq is the change in Y from Y(0) to 
saturation i.e. the [3H]-activity when the reaction reaches equilibrium. For each RyR2 variant, the fitted values 
for K were compared using one-way ANOVA with Holm-Sidak’s multiple comparisons correction, p < 0.05 
considered significant. Using the same approach, the fitted values for the Beq were compared between RyR2 
variants for reactions without CaM added. 
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Endoplasmic reticulum luminal Ca2+ imaging of HEK293 cells expressing RyR2 during Store-Overload 
Induced Ca2+ Release (SOICR)
Single-cell endoplasmic reticulum (ER) luminal Ca2+ imaging of HEK293 cells expressing RyR2 
variants was done as previously described [7]. Briefly, HEK293 cells stably expressing murine RyR2 variants 
were co-transfected with plasmids encoding CaM and the D1ER Ca2+ probe. The D1ER FRET signals, 
reflecting ER luminal free Ca2+ in individual cells, were monitored using an epi-fluorescent microscope during 
perfusion [7,62]. High extracellular Ca2+ concentration (2 mM) increased ER Ca2+ load, ultimately causing ER 
Ca2+ load oscillations due to RyR2 SOICR (Figure 5A and caption). The oscillating D1ER FRET signal time 
trace from each cell was used to measure the Ca2+ release properties of the RyR2 channels relative to the ER 
Ca2+ store capacity: the activation and termination thresholds, and with their difference taken as the fractional 
ER Ca2+ release (Figure 5A). The ER Ca2+ store capacities were calculated from the difference between FRET 
signal’s maximum and minimum (Fmax - Fmin). Three different CaM expression conditions were used with each 
of the RyR2-CaMBD variants (Table 1): endogenous CaM, and plasmid expression of either CaM or -N54I. 
An average measurement included imaging of 2-4 cover slips each yielding 5-20 single-cell FRET time traces, 
and 2-3 sets of measurements were done for each combination of RyR2 and CaM variants. The RyR2 Ca2+ 
release properties calculated for each of these time traces were aggregated to one data set (Table 4). 
The measured RyR2 Ca2+ release properties passed a normality test (D’Agostino-Pearson) and were 
compared using two different one-way ANOVAs with Dunnett's correction for multiple comparisons, p < 0.05 
considered significant. One test was done for the effect of each RyR2 mutation within each CaM-expression 
condition with values compared to those for RyR2-WT. And then a second test for the effect of each of the 
three CaM expression conditions within each RyR2 variant with values compared to those for the condition 
with CaM plasmid expression. The purpose of the double analysis was to investigate both inherent effects of 
the RyR2 mutations and, separately, the effect of CaM-expression on each RyR2 variant. All the measured 
store capacities were evaluated using a one-way ANOVA with a Tukey’s multiple comparisons correction for 
all possible combinations with no significant differences identified. All data points used for statistical analysis 
and figure plotting are available as supplemental data (Supplemental_data_table_1.csv).
HEK293 cells have an endogenous ER Ca2+ release mechanism mediated by the inositol triphosphate 
receptor. However, cells not modified for RyR2-expression do not show any changes in ER Ca2+ load under the 
conditions used to induce RyR2-mediated SOICR [7,41,50,66].
Estimation of CaM expression levels in HEK293 Cells
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HEK293 cells expressing RyR2-WT were cultured as described above, and cell lysates prepared from 
the plasmid transfected cells were used for Western blotting for CaM as previously described (Figure 10) [16]. 
The primary antibodies Ab124742 (Abcam, Cambridge, UK) and A5316 (MilliporeSigma, Massachusetts, 
USA) were used for detecting CaM and actin. CaM and acting protein band intensities on the Western-blotted 
membranes were quantified using ImageJ, and the protein levels of total CaM in individual samples were 
normalized to that of -actin [16,72]. Western blot analysis was done in triplicates, and expressions levels were 
compared for all possible combinations using one-way ANOVA with a Tukey multiple comparisons correction, 
p < 0.05 considered significant. Plasmid expression of either CaM-WT or CaM-N54I significantly increased 
total CaM protein 2-fold 1.8-fold (+/- 0.3) compared to endogenous CaM protein levels (Ctrl). No significant 
difference in the total CaM protein level was observed comparing plasmids expression of CaM-WT and CaM-
N54I.
Endoplasmic reticulum luminal Ca2+ imaging of permeabilized HEK293 cells Expressing RyR2 with 
sustained 1 M cytosolic Ca2+
Measurements of permeabilized HEK293 single cell’s steady-state ER Ca2+ load during perfusion with 
sustained 1 μM [Ca2+]free was done as previously described with modifications [39,52]. Briefly, RyR2 
expressing HEK293 cells were permeabilized by perfusion with 0.25 g/L saponin in Ca2+ free intracellular-like 
medium (ICM: 125 mM KCl, 19 mM NaCl, 10 mM HEPES, 2 mM ATP, 2 mM MgCl2, and 50 M EGTA at 
pH 7.4) for 1-2 min. The extent of permeabilization was continuously monitored and then halted by switching 
to ICM with 0.1 M [Ca2+]free for another 4 min. The D1ER FRET signal from single cells was then recorded 
during five different perfusion conditions (Figure 7): 0.1 M [Ca2+]free, 1 M [Ca2+]free, 1 M [Ca2+]free + 0.5 M 
purified CaM, 0.1 M [Ca2+]free + 1 mM tetracaine and finally 0.1 M [Ca2+]free + 10 mM caffeine, all in ICM. 
All perfusions were done for 6 min, except for ICM with 0.1 M [Ca2+]free which was for 4 min. Perfusion rate 
was ~1.5 mL/min into an ~0.5 mL perfusion chamber. The first steps with permeabilization and perfusion 
without Ca2+ washed out endogenous CaM as evident from the stable steady-state ER Ca2+ load obtained at 1 
M [Ca2+]free before the addition of CaM [39].
 An average measurement included imaging of 1-2 cover slips each yielding 5-10 single-cell FRET time 
traces, and 2 sets of measurements were done for each combination of RyR2 and CaM variants (Table 5). The 
steady-state ER Ca2+ load was measured as the 1 min averaged FRET signal at the end of each perfusion step 
relative to the ER store capacity (Figure 7 and caption). All the measured steady-state ER Ca2+ loads were 
compared for all possible combinations using a Kruskal-Wallis test with a Dunn’s multiple comparisons 
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correction, p < 0.05 considered significant. All data points used for statistical analysis and figure plotting are 
available as supplemental data (Supplemental_data_table_2.csv).
Caffeine induced Ca2+ release in HEK293 cells 
Using the fluorescence Ca2+ indicator Fluo-3 AM (#F1221, Thermo Fischer Scientific), bulk cytosolic 
Ca2+ concentration was monitored in suspensions of RyR2-expressing HEK293 cells during caffeine additions, 
as previously described with minor modifications [52]. Briefly, HEK293 cell lines modified for expressing 
RyR2 variants were grown on 10 cm culture dishes (#83.3902, Sarstedt, Nümbrecht, North Rhine-Westphalia, 
Germany) until ~80 % confluence and the RyR2 expression induced by changing medium to one supplemented 
with 1 μg/mL tetracycline. After ~24 h of induced growth, cells were detached and loaded with Fluo-3 AM 
before wash with buffer. The Fluo-3 fluorescence was continuously measured in a spectrofluorometer (SLM-
Aminco series 2) during repeated additions of caffeine. Caffeine addition elicited a RyR2-mediated Ca2+ 
release which transiently increased [Ca2+]cyt, i.e. a Fluo-3 fluorescence peak, and additions were spaced 90 s for 
[Ca2+]cyt to return to basal levels before next addition (Figure 9A). Time traces of Fluo-3 fluorescence were 
normalized to the initial fluorescence intensity and a baseline correction done for each addition-segment to 
correct for cell suspension dilution (F/F0) and caffeine fluorescence quenching. The caffeine response peak 
heights were measured for each addition, normalized to the maximum peak height in each trace, and plotted as 
normalized peak heights as a function of the cumulative caffeine concentration (Figure 9B). Significant 
differences in the caffeine responses between RyR2 and deletion variants were evaluated, at each cumulative 
caffeine concentration, using two-way ANOVA with a Dunnett’s multiple comparisons correction, p < 0.05 
considered significant. Using the integrated peak areas, instead of maximum heights, gave identical results (not 
shown). Measurements were done in at least triplicates.
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TABLES
Table 1: RyR2 CaM-binding domains investigated and RyR2 variants used in this study. Amino acid 
numbering corresponds to human RyR2 (UniprotKB Q92736) where nothing else is mentioned. RyR2 
mutations were introduced in the mouse RyR2 cDNA and transfected into HEK293 Flp-In cells. The human 
and mouse RyR2 proteins differ minutely such that human RyR2 CaMBD numbering corresponds to mouse 
RyR2 numbering +1. See alignment in Figure 2.
CaMBD Residues
RyR2 mutation
(murine)
RyR2 
variant
Comments References
CaMBD1a
F1942 - 
R1966
F1941-T1961
RyR2-
CaMBD1a
Extrapolated from apoCaM 
binding to RyR1
[15,46,65]
CaMBD1b
L2029 - 
S2056
L2028-A2048
RyR2-
CaMBD1b
Encompasses the S2031 
phosphorylation site and a 
putative CaM binding motif
[46,64,73]
CaMBD2
R3581 - 
P3607
K3582-F3602
RyR2-
CaMBD2
Well-established and pivotal 
for CaM-RyR2 interaction
[5,15,17,46]
CaMBD3
F4246 - 
V4276
F4245-K4265
RyR2-
CaMBD3
CaM’s affinity for CaMBD2 
and -3 are similar at the 
peptide level
[15,46]
Table 2: RyR2 CaMBD peptides used in this study. Numbering corresponds to human RyR2 (UniprotKB 
Q92736).
Nomenclature RyR2 Residues Peptide Sequence (Length) Ref
CaMBD1a R1941 - F1965 RFRYNEVMQALNMSAALTARKTKEF (25) [15,46,65]
CaMBD1b D2022 - S2052 DLTIRGRLLSLVEKVTYLKKKQAEKPVESDS (31) [46,64,73]
CaMBD2 R3581 - L3611 RSKKAVWHKLLSKQRKRAVVACFRMAPLYNL (31) [8,16,25,46]
CaMBD3 F4246 - V4276 FALRYNILTLMRMLSLKSLKKQMKKVKKMTV (31) [15,46]
Table 3: Fitted dissociation constants from CaM titrations of RyR2 CaMBD1a and CaMBD1b peptides. Go 
and data are only shown for [Ca2+]free were KD or KDI values were significantly different for CaM-N54I 
compared to CaM-WT. KD, KDI and [Ca2+]free are given in M, and Go in kJ/mol.
KDI for binding to CaMBD1a KD for binding to CaMBD1bA
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[Ca2+]free CaM-WT CaM-N54I Go CaM-WT CaM-N54I Go
2 1.51 1.88 0.5 0.33 0.44 0.7
4 0.64 0.90 0.9 0.14 0.21 1.1
10 0.27 0.43 1.1 0.07 0.12 1.6
25 0.14 0.21 1.1 0.04 0.08 1.8
100 0.10 0.13 0.7 0.02 0.06 2.0
398 0.08 0.11 0.6 0.03 0.05 1.6
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Table 4: Quantified Ca2+ release properties for RyR2 variants investigated in intact HEK293 cells. Activation 
and termination thresholds as well as fractional ER Ca2+ release are given in units of % with SD in parentheses 
(see Figure 5).
RyR2 variant / 
CaM plasmid expression
Activation
Threshold
Termination
Threshold
Fractional
Ca2+ Release
Analysed
Traces
RyR2 WT 89 (4.7) 58 (5.2) 31 (5.4) 108
RyR2 WT + CaM 90 (4.2) 62 (5.9) 29 (5.2) 50
RyR2 WT + CaM-N54I 85 (6.3) 49 (5.2) 36 (6.7) 47
RyR2-CaMBD1a 98 (3.2) 36 (7.3) 61 (6.9) 55
RyR2-CaMBD1a + CaM 100 (2.0) 57 (5.8) 44 (6.9) 4
RyR2-CaMBD1a + CaM-N54I 97 (2.8) 42 (7.1) 55 (7.6) 23
RyR2-CaMBD1b 83 (6.6) 58 (7.2) 25 (4.8) 93
RyR2-CaMBD1b + CaM 85 (4.5) 63 (5.7) 22 (3.8) 32
RyR2-CaMBD1b + CaM-N54I 83 (4.0) 53 (6.7) 31 (5.9) 25
RyR2-CaMBD2 93 (3.2) 35 (6.1) 57 (7.4) 69
RyR2-CaMBD3 88 (4.7) 58 (7.0) 30 (6.3) 57
RyR2-CaMBD3 + CaM 91 (5.2) 64 (4.2) 27 (4.3) 22
RyR2-CaMBD3 + CaM-N54I 87 (6.3) 49 (7.2) 38 (6.5) 37
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Table 5: Steady-state ER Ca2+ load in permeabilized HEK293 cells expressing RyR2 variants, and with 1 M 
cytosolic side [Ca2+]free. The steady-state ER Ca2+ load without CaM or with CaM-WT or -N54I added to 
perfusion medium are listed. ER Ca2+ load and the effect of CaM are given in units of % with SD in 
parentheses (see Figure 8). Also provided are the number of analysed microscope cover slips with cells (slips) 
and the corresponding number of single cell traces (traces) analysed.
RyR2-WT
RyR2-
CaMBD1a
RyR2-
CaMBD1b
RyR2-
CaMBD2
RyR2-
CaMBD3
no CaM 32 (9.9) 31 (12) 31 (9.4) 33 (11) 30 (7.7)
+ CaM-WT 41 (12) 54 (15) 39 (10) 34 (11) 39 (8.6)
Steady-state ER 
Ca2+ load
+ CaM-N54I 27 (7.1) 41 (13) 25 (4.5) n/a 23 (6.2)
CaM-WT 9.1 (4.6) 21 (8.0) 6.5 (5.1) 1 (2.8) 7.9 (4.2)
Effect of CaM
CaM-N54I -3.7 (2.6) 15 (8.4) -4.3 (2.3) n/a -4.3 (4.1)
using CaM-WT 10 / 197 11 / 126 7 / 163 4 / 82 5 / 85
Slips / traces
using CaM-N54I 4 / 66 5 / 56 3 / 46 n/a 7 / 150
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FIGURE LEGENDS
Figure 1: Locations of CaM and RyR2 CaMBDs on the homotetrameric RyR2 channel. Structural details 
from two cryo-EM structures of the RyR2-CaM complex under different Ca2+ conditions are shown. Three 
RyR2 monomers are semi-transparent to emphasise the one inspected closer. Left: Images of a RyR2-CaM 
structure also containing peptidyl-prolyl cis-trans isomerase FKBP1B (FKBP12.6) and obtained in the absence 
of Ca2+ (PDB file 6JI8). Right: Images from a RyR2-CaM structure obtained in the presence of Ca2+ (PDB file 
6JV2). The RyR2 channel is shown in side-view with a smaller top-view inserted (A-B), and for each structure 
a zoom on the CaM-binding region is shown in two representations: C-D) Close-up view of CaM bound to 
RyR2 in surface representation, and E-F) detailed view further zoomed in and with details in protein secondary 
structure representation. Amino acids part of RyR2 CaMBD1a, -1b and 2 are colour-highlighted, and so are the 
amino acids nearest to CaMBD3 (colour legend in figure). The CaM N-domain is shown in blue and the C-
domain in orange throughout. Methionine residues part of the CaM N-domain’s binding groove are highlighted 
in white. Note that Asn-54 (highlighted as red dots in E-F) is not buried in RyR2 in either CaM conformation. 
RyR2 Phe-3603 and Trp-3587 are highlighted as green stick models. Rotation axis indicate structure 
translocation from top views to side views (inserts to A-B), and from side-views to zoomed views of CaM (A-
B to C-F).  
Figure 2: RyR sequence alignment for regions around CaMBDs. Partial alignment shown for human RyR 
(hRyR1-3) and mouse RyR2 (mRyR2). The protein sequence alignment was made  using ClustalW and 15 
RyR sequences from human, mouse, rabbit, chicken, zebrafish, C. elegans, D. melanogaster and O. dioica 
[63]. UniprotKB files P21817, Q92736, Q15413, E9PZQ0, E9Q401, A2AGL3, P11716, P30957, Q9TS33, 
F1NLZ9, Q90985, A6P4B8, P91905, Q24498, E4XPI8. Bars reflect the degree of conservation across all 15 
aligned RyR sequences. Investigated RyR2 CaMBDs are highlighted in yellow, and the residues deleted in the 
murine RyR2-CaMBD variants are underlined in red. CaM-binding motifs, identified by searches using the 
calmodulin target database, are lined above in grey.
Figure 3: Ca2+-dependent affinities of CaM-WT and -N54I for binding to RyR2 CaMBD peptides. The 
dissociation constants for the binding of CaM to peptides  (KD, or KDI for RyR2 CaMBD1a titrations) are 
plotted for discrete [Ca2+]free. Dashed, connecting lines are added to ease overview only. Note the double 
logarithmic axes. Asterisks indicate significant differences in KD or KDI between CaM-WT and -N54I for 
binding to CaMBD1a and CaMBD1b peptides, also summarized in Table 3 (unpaired t-tests with Holm-Sidak 
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correction, p < 0.05). There were no significant differences between CaM-WT and -N54I in the fitted KD for 
their affinity for binding to RyR2 CaMBD2 and nor for their binding to CaMBD3.
Figure 4: [3H]ryanodine binding to RyR2 variants at 1 M [Ca2+]free. A) Cell lysates from HEK293 
expressing RyR2 variants were incubated with [3H]ryanodine and without (black), with purified CaM-N54I 
(tangerine) or with CaM-WT (grey). The extent of [3H]ryanodine binding to RyR2 was quantified using 
scintillation counting and normalized to lysate protein concentration (0.5-0.8 g/L) such that y-axis units are 
countsLh-1g-1. Solid lines show fits to a one-phase association model. Note the different y-axis ranges in each 
panel. B) Estimation of the extent of [3H]ryanodine binding to RyR2 at the reaction equilibrium (Beq, see 
‘Materials and methods’). Comparisons were made for the reactions without CaM added, and asterisk indicate 
values significantly different from the Beq for RyR2-WT (1-way ANOVA with Holm-Sidak correction, p < 
0.05). C) Effects of CaM on the association rate of [3H]ryanodine to each RyR2 variant. Asterisks indicate an 
association rate significantly different from that of the reaction without CaM added (1-way ANOVA with 
Holm-Sidak correction, p < 0.05). Error bars show the sample standard deviation (SD) in all panels and four 
replicates were made for each reaction.
Figure 5: Store overload-induced Ca2+ release in RyR2-expressing HEK293 cells. Example time traces for 
the FRET signal from the ER luminal D1ER Ca2+ probe, oscillating with RyR2 Ca2+ releases. FRET is 
measured as the ratio of yellow to cyan D1ER protein fluorescence (YFP/CFP).  Concentrations of Ca2+, 
tetracaine and caffeine in the perfusion solution are shown in rectangles. Increasing extracellular Ca2+ 
concentration elicited RyR2 SOICR oscillations, tetracaine blocked Ca2+ release thereby filling ER to 
maximum ER Ca2+ load, and caffeine opened RyR2 channels depleting ER Ca2+. Tetracaine and caffeine were 
used to establish FRET signals for maximum and minimum ER Ca2+ load (Fmax and Fmin), respectively. The 
activation and termination thresholds, and the fractional ER Ca2+ release were calculated relative to Fmax and 
Fmin. One example FRET trace is shown for single cells expressing either RyR2, -CaMBD1a, -CaMBD1b or 
-CaMBD3, and all with CaM-WT plasmid expression. The full data set from the individual analysis of 
hundreds of such single cell traces is shown in Figure 6 and Table 4.
Figure 6: Ca2+ release properties of RyR2 and CaMBD deletion variants during SOICR. Plots show the 
activation threshold (A), termination threshold (B) and fractional ER Ca2+ release (C) averaged from multiple 
traces (means with 95 % confidence interval (CI)). For each RyR2 variant, three conditions of CaM expression 
were assayed: endogenous CaM (control), and CaM or CaM-N54I transient expression. RyR2-CaMBD2 does A
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not respond to CaM expression condition, hence only one condition. For each RyR2 variant, asterisk (*) 
indicates significant differences between the condition with CaM-WT expression and endogenous or CaM-
N54I expression  (1-way ANOVA with Dunnett's correction, p < 0.05). Plus (+) indicates significant 
differences between the RyR2-WT and each RyR2 CaMBD deletion variant given the same CaM expression 
condition (1-way ANOVA with Dunnett's correction, p < 0.05). Measured values and number of replicates are 
summarized in Table 4.
Figure 7: RyR2 Ca2+ release in permeabilized RyR2-expressing HEK293 cells. Example D1ER FRET 
signal from permeabilized cells (3-5 averaged) perfused with sustained, cytosolic side Ca2+. YFP/CFP is the 
difference between the D1ER FRET minimum signal (Fmin) and the FRET signal at each time point (baseline 
subtraction). Five different cell lines (A-E) expressing either RyR2-WT, -CaMBD1a, -CaMBD1b, -
CaMBD2 or -CaMBD3 were used with either CaM-WT (grey) or CaM-N54I (tangerine) addition. The 
continuous ER Ca2+ release (RyR2) and Ca2+ uptake (SERCA2b) establishes a steady-state ER Ca2+ load during 
each perfusion condition (labelled rectangles). Tetracaine (1 mM) and caffeine (20 mM) were used to establish 
FRET signals for maximum and minimum ER Ca2+ load (Fmax and Fmin). Steady-state ER Ca2+ load at 1 μM 
[Ca2+]free was the average FRET signal, relative to Fmax – Fmin, during perfusion without (F1.0) and with CaM 
added (FCaM-WT or FCaM-N54I). The differences FCaM-WT - F1.0 or FCaM-N54I - F1.0 quantify the effects on steady-state 
ER Ca2+ load from adding CaM-WT or -N54I. RyR2-CaMBD2 is insensitive to regulation by CaM and was 
included as a control and therefore only perfused with CaM-WT. The traces shown are examples of the type of 
experiment data obtained, and the full data set from the individual analysis of hundreds of such single cell 
traces is shown in Figure 8 and Table 5.
Figure 8: Measured steady-state ER Ca2+ load in the presence of sustained 1 M cytosolic Ca2+ in 
permeabilized HEK293 cells expressing RyR2 variants. A) Plot of the measured steady-state ER Ca2+ loads 
before (no CaM, green) and after the addition of purified CaM-WT (grey) or CaM-N54I (tangerine). B) The 
quantified effects of adding CaM-WT or CaM-N54I to permeabilized cells measured as the change in steady-
state ER Ca2+ load compared to the condition without CaM. Note that percent is used as the unit for ER Ca2+ 
load and not as a measure of relative change (see ‘Materials and methods’). For both A and B, lower case 
letters (a, b, c or d) indicate groups of averages significantly different from all other groups while asterisk (*) 
indicates a value distinct from all others except for the effect of CaM-WT on RyR2-WT (Kruskal-Wallis test 
with Dunn’s correction, p < 0.05). Error bars correspond to the 95 % CI, and mean values and number of 
replicates are summarized in Table 5.A
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Figure 9: Caffeine stimulated RyR2-mediated Ca2+ release in HEK293 cell suspensions. A) Cells 
expressing RyR2 variants were loaded with a cytosolic Ca2+ indicator (Fluo-3), and each caffeine addition 
caused a transient increase in fluorescence (a peak). Example time traces are shown as normalized Fluo-3 
fluorescence (F/F0) as a function of the cumulative caffeine concentration. B) RyR2 Ca2+ release profiles 
quantified from time traces. Data points represent the normalized peak heights for each caffeine addition (see 
‘Materials and methods’). Solid lines are biphasic Hill fits for overview purposes only. Error bars show 
standard error of the mean from at least triplicate measurements. Filled-in symbols indicate points significantly 
different from the response of RyR2-WT (2-way ANOVA with Dunnett's correction, p < 0.05). The RyR2-
CaMBD1a and RyR2-CaMD1b differed significantly from that of RyR2-WT at six out of eight cumulative 
caffeine concentrations.
Figure 10: Estimation of CaM expression levels in HEK293 cells. A) HEK293 cell lysates were Western-
blotted for CaM and -actin with bands visualized using chemiluminescence imaging. HEK293 cells were 
cultured without (Ctrl) and with plasmid expression of either CaM-WT or CaM-N54I (samples loaded left to 
right, and experiment done in triplicate). B) Quantified CaM expression levels in HEK293 cells. Protein 
expression levels of CaM were normalized to that of -actin, and plasmid expression of either CaM variant 
significantly increased total CaM protein levels, compared to the control. Error bars correspond to SD. a or b 
indicate groups of averages significantly different from all others (one-way ANOVA with Tukey’s correction, 
p < 0.05). No significant difference in CaM protein levels were observed comparing plasmid expression of 
CaM-WT and CaM-N54I. 
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SUPPORTING INFORMATION
Supplemental_data_table_1.csv contains all data points used for analysing the experiment using SOICR in 
RyR2-expressing HEK293 cells during single cell ER Ca2+ imaging. Data was used to prepare Table 4 and 
Figure 6.
Supplemental_data_table_2.csv contains all data points used for analysing the experiment using permeabilised, 
RyR2-expressing HEK293 cells added purified CaM during single cell ER Ca2+ imaging. Data was used to 
prepare Table 5 and Figure 8.
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